Q-linea Announces ASTar® Contract With Large Health System in the U.S. Mid-Atlantic Region
Q-linea Announces ASTar® Contract With Large Health System in the U.S. Mid-Atlantic Region
Q-linea AB (publ) announces today that it has signed a contract with a major U.S. health system in the mid-Atlantic region for deployment of its ASTar® rapid antimicrobial susceptibility testing (AST) system.
This installation will serve an integrated network with more than 1,500 hospital beds with a strong reputation for clinical excellence and innovation. The installation represents an important milestone for Q-linea’s U.S. business as it is the first new deployment following FDA clearance of the expanded panel.
“This contract represents a major step forward for Q-linea in the United States,” said Stuart Gander, President and CEO of Q-linea. “We are pleased to see that the leading healthcare systems are looking to ASTar to serve high-volume laboratories efficiently while delivering improved patient testing for their clinical teams.”